Paid Clinical Trials South Dakota
Discover 347 paid clinical trials in South Dakota. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
PegozaferminA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Sponsor:
89bio, Inc.
Location:
Code:
NCT06419374
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Pegozafermin
Placebo
NNC0487-0111A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
Sponsor:
Novo Nordisk A/S
Location:
Code:
NCT06542874
Conditions
Type 2 Diabetes (T2D)
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
NNC0487-0111 subcutanous
Placebo (NNC0487-0111 subcutanous)
NNC0487-0111 oral
Placebo (NNC0487-0111 oral)
Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT04071457
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Lenalidomide
Daratumumab/rHuPH20
Selumetinib vs. Carboplatin/VincristineA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
CamizestrantAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Sponsor:
AstraZeneca
Location:
Code:
NCT05952557
Conditions
Breast Cancer, Early Breast Cancer
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Camizestrant
Tamoxifen
Anastrozole
Letrozole
Exemestane
MilvexianA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT05754957
Conditions
Acute Coronary Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Milvexian
Placebo
Nivolumab, Ipilimumab, CabozantinibTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03866382
Conditions
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography Test
Observational StudyPTSD, AUD, and Interpersonal Conflict: Within-person Associations
Sponsor:
University of South Dakota
Location:
Code:
NCT04552782
Conditions
Stress Disorders, Post-Traumatic
Alcoholism
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Alcohol CBM
PTSD CBM
Alcohol Sham
PTSD Sham
SaruparibSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Sponsor:
AstraZeneca
Location:
Code:
NCT06120491
Conditions
Metastatic Castration-Sensitive Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Saruparib
Placebo
Abiraterone Acetate
Darolutamide
Enzalutamide